Abstract: The present invention provides co-crystals of the anaplastic lymphoma kinase (ALK) and its ligand ALKAL2 and the related leukocyte tyrosine kinase (LTK) and its ligand ALKAL1. The invention also provides computer-assisted and other methods for selecting molecules able to modulate the interaction between ALK, LTK and their respective ligands.

Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

Abstract: A method may include obtaining, by a processing device, a workflow object that includes a plurality of workflow entity objects and one or more data objects, and executing a workflow by identifying, from the application objects, an application object that corresponds to a first application, wherein the workflow associates the application with at least one of the data objects, determining, whether the first application has permission to access the data object according to a data policy associated with the data object, wherein the data policy specifies one or more data access criteria, wherein the first application has permission to access the data object in response to one or more of the workflow entity objects that are associated with the data object satisfying the data access criteria, and responsive to determining that the first application has permission to access the data object, executing the first application in a secure enclave.

Abstract: A method may include obtaining, by a processing device, a workflow object that includes a plurality of workflow entity objects and one or more data objects, and executing a workflow by identifying, from the application objects, an application object that corresponds to a first application, wherein the workflow associates the application with at least one of the data objects, determining, whether the first application has permission to access the data object according to a data policy associated with the data object, wherein the data policy specifies one or more data access criteria, wherein the first application has permission to access the data object in response to one or more of the workflow entity objects that are associated with the data object satisfying the data access criteria, and responsive to determining that the first application has permission to access the data object, executing the first application in a secure enclave.

Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

Abstract: The present invention relates to monomeric fusion proteins comprising the extracellular part of the thymic stromal lymphopoietin receptor (TSLPR) and the extracellular part of the interleukin-7 receptor alpha (IL-7Ralpha) as inhibitors of thymic stromal lymphopoietin (TSLP) activity. The invention relates further to the use of said inhibitors as a medicament in the treatment of—but not limited to—inflammatory diseases, cancer and fibrosis.

Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

Abstract: The present invention relates to monomeric fusion proteins comprising the extracellular part of the thymic stromal lymphopoietin receptor (TSLPR) and the extracellular part of the interleukin-7 receptor alpha (IL-7Ralpha) as inhibitors of thymic stromal lymphopoietin (TSLP) activity. The invention relates further to the use of said inhibitors as a medicament in the treatment of—but not limited to—inflammatory diseases, cancer and fibrosis.

Abstract: The present invention relates to the crystal structure of Flt3 and its cognate ligand FL. In particular, the binding interface of Flt3 and its cognate ligand FL has been determined. The present invention also relates to the applicability in modulating Flt3 activity. Methods for the identification as well as the rational design of mediators of Flt3 signaling are disclosed. In an aspect the method comprises a step of employing the atomic coordinates representing the three-dimensional structure of Flt3 and/or FL.